IgA nephropathy in MPN

Current understanding

IgA nephropathy has been observed as a concurrent renal complication in polycythemia vera, potentially driven by JAK-STAT-mediated IL-6/IL-11 signaling promoting mesangial proliferation and aberrant hematopoietic IgA production. A single case report documents that ruxolitinib therapy reduced proteinuria and stabilized renal function, suggesting JAK inhibition may have disease-modifying effects on MPN-associated glomerulonephritis. Evidence base is limited to one case report.

Evidence log

• 2026-04-27 — JAK Inhibitor-Induced Improvement of IgA Nephropathy in a Patient With Polycythemia Vera: A Case Report.: cross-connection with lysozyme-associated-nephropathy-symptom: Both are MPN-associated renal complications in which ruxolitinib has been reported to stabilize renal function, suggesting JAK inhibition may have broader nephroprotective effects across distinct MPN glomerular/tubular pathologies. (novelty: 4)

Open questions

Related